Croda International (6CMB) Q2 2026 Earnings Report

The call presented a broadly positive operational and financial picture: organic growth, margin expansion, improved EPS and cash flow, strong outperformance in Consumer Care (notably Beauty Actives) and progress on transformation and AI initiatives. Headwinds remain in certain areas — Pharma Solutions phasing and lumpiness, Crop Protection weakness, regional F&F disruption, working-capital outflow and input-cost volatility — but management reiterated FY guidance and a clear path to their 3-year targets, viewing many challenges as within management control.

Management reiterated full‑year 2026 guidance: organic sales growth of 3–6% and a further increase in adjusted operating margin, with adjusted operating profit expectations unchanged, and said the group remains on track to deliver its 2028 financial framework. In H1 the business delivered sales +5% to £881m (new & protected products +7%), volumes +1%, price/mix +4%; adjusted operating profit +7% to £156m, EBITDA £208m, EPS +9% to 78p, free cash flow £38m (vs £28m), net debt £578m and leverage ~1.4x. Margins expanded 50bps to 17.7% aided by £18m of transformation savings in H1 (cumulative £46m) against a £100m transformation target; management expects operating margins to increase sequentially in H2, Pharma Solutions project revenues to recover in H2, working capital (H1 outflow £68m) to improve as a programme delivers ~£50m structural savings by 2028 (offsetting a £20–30m p.a. growth drag), and H1 capex was £43m.